Sequential interferon-alpha and beta treatment in patients with chronic hepatitis C

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis C is a significant global health concern.
• Interferon (IFN) therapy has been used to treat chronic hepatitis C.
• Sequential treatment regimens are explored to improve outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of a sequential treatment protocol using interferon-beta followed by interferon-alpha for chronic hepatitis C.
• To identify predictors of sustained virologic response in patients undergoing this sequential IFN regimen.

Main Methods:

• A trial involving 25 patients with chronic hepatitis C.
• Patients received natural human IFN-beta (6 MU daily for 2 weeks) followed by natural human IFN-alpha (6 MU thrice weekly for 10-22 weeks).
• Outcomes assessed included serum alanine aminotransferase (ALT) normalization, hepatitis C virus (HCV) RNA levels, Knodell's fibrosis score, and indocyanine green retention rate.

Main Results:

• 40% of patients achieved sustained ALT normalization for at least 24 weeks; 40% of these had undetectable HCV RNA.
• Predictors for sustained response included low serum HCV RNA, low Knodell's fibrosis score, and low indocyanine green retention.
• Mild, transient side effects like elevated ALT and proteinuria were noted during IFN-beta treatment.

Conclusions:

• Sequential IFN-alpha and IFN-beta treatment did not offer additional antiviral effects for chronic hepatitis C.
• The regimen was completed by all patients with manageable side effects.
• Predictive factors for sustained response were identified, suggesting potential for personalized treatment approaches.